Related Experiment Videos
[Clinical studies on aspoxicillin in the field of pediatrics]
Insights
Aspoxicillin (ASPC), a new penicillin antibiotic, showed an 83.3% efficacy rate in treating pediatric bacterial infections. This new antibiotic demonstrated excellent bacteriological efficacy with no observed clinical side effects.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Background:
- A new semisynthetic penicillin, aspoxicillin (ASPC), was evaluated for its clinical efficacy and safety.
- The study aimed to assess ASPC's effectiveness in treating various pediatric bacterial infections.
Observation:
- ASPC was administered intravenously to 12 pediatric patients with pneumonia, tonsillitis, purulent lymphadenitis, and urinary tract infections.
- Dosage ranged from 57.7-129.0 mg/kg, administered three to four times daily for 4-7 days.
Findings:
- An overall efficacy rate of 83.3% was observed, with excellent efficacy in 66.7% of patients.
- Bacteriological efficacy was excellent, with eradication of all 6 tested bacterial strains.
- No clinical side effects were reported; minor laboratory abnormalities (elevated GOT/GPT, eosinophilia) occurred in 3 patients.
Implications:
- Aspoxicillin (ASPC) demonstrates significant potential as a valuable antibiotic for pediatric bacterial infections.
- The favorable efficacy and safety profile suggest ASPC warrants further investigation and consideration in clinical practice.
- Further research could explore ASPC's role in broader pediatric infectious disease management.
Abstract:
Clinical studies were performed as follows on aspoxicillin (ASPC), a new semisynthetic penicillin. ASPC was intravenously given to 12 patients in doses of 57.7-129.0 mg/kg on average) t.i.d. or q.i.d. for 4-7 days (5.7 days on average): 9 with pneumonia, 1 with tonsillitis, 1 with purulent lymphadenitis and 1 with urinary tract infection. The overall efficacy rate was 83.3%, i.e. efficacy was excellent in 8 (66.7%), good in 2 (16.7%), fair in 1 (8.3%) and poor in 1 (8.3%). Bacteriological efficacy was excellent, i.e. 6 of the 6 strains disappeared. No clinical side effects were observed during treatment. Laboratory abnormalities were observed in 3 cases, slight elevation of GOT in 1, slight elevations of GOT and GPT in 1 and mild eosinophilia in 1. The above results suggest that ASPC is an useful antibiotic for treating pediatric bacterial infections.